Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies
Summary
Picard Medical says its SynCardia subsidiary completed successful preclinical implant studies for the next-generation Emperor Total Artificial Heart. The company reports that the device provided stable full circulatory support across three acute animal implant procedures. The latest design adds an independent dual motor ventricular system intended to improve physiologic responsiveness and move the program toward a fully implantable artificial heart. The release frames the study as a milestone in ongoing translational development, while noting that the device is still under development and has not received FDA approval or clearance. This update reinforces continued work with clinical and research partners at the University of Arizona and Banner University Medical Center.